| P50 | author | Joseph B Domachowske | Q56953693 |
| P2093 | author name string | H F Rosenberg | |
| P2860 | cites work | Surfactant therapy for bronchiolitis in critically ill infants | Q24245016 |
| | Identification of nucleolin as a cellular receptor for human respiratory syncytial virus | Q28245563 |
| | Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection | Q33591425 |
| | Surfactant protein-A enhances respiratory syncytial virus clearance in vivo | Q33848860 |
| | Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model | Q33901537 |
| | Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection | Q34072674 |
| | Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus | Q34118491 |
| | Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment | Q34280641 |
| | Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents | Q34465570 |
| | The use of a neonatal mouse model to study respiratory syncytial virus infections | Q34549253 |
| | Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. | Q34647519 |
| | The burden of respiratory syncytial virus infection in young children | Q34938343 |
| | Role of CCL5 (RANTES) in viral lung disease. | Q35024052 |
| | IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. | Q35069985 |
| | Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice | Q35076998 |
| | Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma | Q35097216 |
| | Animal models of human respiratory syncytial virus disease | Q35159747 |
| | Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus | Q35222083 |
| | Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus | Q35535903 |
| | Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo | Q35701867 |
| | The pathogenesis of respiratory syncytial virus infection in cotton rats | Q36058867 |
| | Antisense approaches for inhibiting respiratory syncytial virus | Q36065956 |
| | Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection | Q36114292 |
| | 2-5A antisense treatment of respiratory syncytial virus | Q36218954 |
| | IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus | Q36389523 |
| | Bovine respiratory syncytial virus infection | Q36719904 |
| | Pneumonia virus of mice: severe respiratory infection in a natural host | Q36808322 |
| | Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. | Q36961083 |
| | Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure | Q45723246 |
| | Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis | Q45723418 |
| | Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms | Q45729657 |
| | Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis | Q45731587 |
| | Cytokines in severe respiratory syncytial virus bronchiolitis | Q45732609 |
| | A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome | Q45732622 |
| | Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis | Q45736349 |
| | Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice | Q45738806 |
| | Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis | Q45740212 |
| | Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice | Q45740485 |
| | Cell-Mediated Cytotoxic Responses in Lungs of Cotton Rats Infected with Respiratory Syncytial Virus1,2 | Q45796140 |
| | Primary respiratory syncytial virus infection in mice | Q45833440 |
| | Role of cysteinyl leukotrienes in airway inflammation and responsiveness following RSV infection in BALB/c mice | Q46765194 |
| | Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis. | Q46841986 |
| | Progress in respiratory virus vaccine development | Q56894869 |
| | NK Cell Deficiency Predisposes to Viral-Induced Th2-Type Allergic Inflammation via Epithelial-Derived IL-25 | Q57966252 |
| | Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases | Q70851797 |
| | Serum eosinophil cationic protein and interleukin-5 in children with bronchial asthma and acute bronchiolitis | Q73339919 |
| | The role of TNF-alpha in eosinophilic inflammation associated with RSV bronchiolitis | Q82583647 |
| | Cytokine response after severe respiratory syncytial virus bronchiolitis in early life | Q37004181 |
| | Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation | Q37110768 |
| | Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis | Q37220251 |
| | Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. | Q37340604 |
| | Gene profiling studies in the neonatal ovine lung show enhancing effects of VEGF on the immune response. | Q37467891 |
| | Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection | Q37467898 |
| | Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans | Q37481930 |
| | Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense | Q37663443 |
| | The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus | Q37685176 |
| | Pharmacotherapy of respiratory syncytial virus infection | Q37759642 |
| | The role of respiratory virus infections in childhood asthma inception | Q37804518 |
| | Local cytokine response upon respiratory syncytial virus infection. | Q37825057 |
| | Respiratory syncytial virus prevention and therapy: past, present, and future | Q37857806 |
| | A review of palivizumab and emerging therapies for respiratory syncytial virus | Q37914882 |
| | Oxidant tone regulates RANTES gene expression in airway epithelial cells infected with respiratory syncytial virus. Role in viral-induced interferon regulatory factor activation. | Q38303129 |
| | The histopathology of fatal untreated human respiratory syncytial virus infection | Q38435017 |
| | Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins | Q38625810 |
| | Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. | Q39595322 |
| | Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin | Q40550868 |
| | Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5). | Q40560128 |
| | Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells | Q40662162 |
| | Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent | Q40734229 |
| | The cotton rat model of respiratory viral infections | Q40945079 |
| | Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation | Q40951359 |
| | Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus. | Q41647205 |
| | CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. | Q41944042 |
| | Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. | Q41961873 |
| | Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population | Q43242031 |
| | CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein | Q43690717 |
| | Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection | Q44007532 |
| | A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis | Q44198475 |
| | Zileuton Reduces Respiratory Illness and Lung Inflammation, during Respiratory Syncytial Virus Infection, in Mice | Q44443658 |
| | Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats | Q44677974 |
| | Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo | Q44837083 |
| | RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses | Q45364295 |
| | Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases | Q45390522 |
| | Lung dendritic cells in respiratory syncytial virus bronchiolitis | Q45390524 |
| | Association of TNF-alpha with severe respiratory syncytial virus infection and bronchial asthma | Q45390608 |
| | RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis | Q45398088 |
| | Interleukin (IL)-18 polymorphism 133C/G is associated with severe respiratory syncytial virus infection | Q45398958 |
| | Age-related difference in immune responses to respiratory syncytial virus infection in young children | Q45406543 |
| | Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment | Q45408210 |
| | Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. | Q45418491 |
| | Deletion of CCR1 attenuates pathophysiologic responses during respiratory syncytial virus infection | Q45420156 |
| | Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis | Q45479023 |
| | Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. | Q45496193 |
| | Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection | Q45598082 |
| P433 | issue | 10 | |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1424-1431 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Current Medicinal Chemistry | Q3007710 |
| P1476 | title | Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics | |
| P478 | volume | 19 | |